A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and tolerability, and make a preliminary assessment of
activity, of a combination of pertuzumab and erlotinib in patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC) who have failed on at least one prior
chemotherapy regimen. The anticipated time on study treatment is until disease progression or
unacceptable toxicity, and the target sample size is less than 100 individuals.